• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

石蜡组织中的三种微小RNA组合可作为预测肾细胞癌预后的工具。

A three miRNAs panel in paraffin tissue serves as tool for predicting prognosis of renal cell carcinoma.

作者信息

Chen Wenkang, Wang Wuping, Zhao Zhengping, Wen Zhenyu, Li Yingqi, Ge Zhenjian, Lai Yongqing, Ni Liangchao

机构信息

Guangdong and Shenzhen Key Laboratory of Reproductive Medicine and Genetics, Department of Urology, Peking University Shenzhen Hospital, Shenzhen, China.

Shantou University Medical College, Shantou, Guangdong, China.

出版信息

Front Oncol. 2024 Apr 24;14:1391844. doi: 10.3389/fonc.2024.1391844. eCollection 2024.

DOI:10.3389/fonc.2024.1391844
PMID:38720802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11076680/
Abstract

BACKGROUND

Renal cell carcinoma (RCC) stands as the most prevalent form of urogenital cancer. However, there is currently no universally accepted method for predicting the prognosis of RCC. MiRNA holds great potential as a prognostic biomarker for RCC.

METHODS

A total of 100 cases with complete paraffin specimens and over 5-year follow-up data meeting the requirements were collected. Utilizing the clinical information and follow-up data of the specimens, an information model was developed. The expression levels of eight microRNAs were identified using RT-qPCR. Finally, determine and analyze the clinical application value of these microRNAs as prognostic markers for RCC.

RESULTS

Significant differences were observed in the expression of two types of miRNAs (miR-378a-5p, miR-23a-5p) in RCC tissue, and three types of miRNAs (miR-378a-5p, miR-642a-5p, miR-23a-5p) were found to be linked to the prognosis of RCC. Establish biomarker combinations of miR-378a-5p, miR-642a-5p, and miR-23a-5p to evaluate RCC prognosis.

CONCLUSION

The combination of three microRNA groups (miR-378a-5p, miR-642a-5p, and miR-23a-5p) identified in paraffin section specimens of RCC in this study holds significant potential as biomarkers for assessing RCC prognosis.

摘要

背景

肾细胞癌（RCC）是泌尿生殖系统癌症中最常见的形式。然而，目前尚无普遍接受的预测RCC预后的方法。微小RNA（miRNA）作为RCC的预后生物标志物具有巨大潜力。

方法

收集了100例符合要求的具有完整石蜡标本且随访数据超过5年的病例。利用标本的临床信息和随访数据建立了一个信息模型。采用逆转录定量聚合酶链反应（RT-qPCR）鉴定了8种微小RNA的表达水平。最后，确定并分析这些微小RNA作为RCC预后标志物的临床应用价值。

结果

在RCC组织中观察到两种微小RNA（miR-378a-5p、miR-23a-5p）的表达存在显著差异，并且发现三种微小RNA（miR-378a-5p、miR-642a-5p、miR-23a-5p）与RCC的预后相关。建立miR-378a-5p、miR-642a-5p和miR-23a-5p的生物标志物组合以评估RCC预后。

结论

本研究在RCC石蜡切片标本中鉴定出的三组微小RNA（miR-378a-5p、miR-642a-5p和miR-23a-5p）组合作为评估RCC预后的生物标志物具有巨大潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7d7/11076680/c768807e4b2a/fonc-14-1391844-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7d7/11076680/6c8885d4eeb1/fonc-14-1391844-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7d7/11076680/dbcfe748e6e3/fonc-14-1391844-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7d7/11076680/c768807e4b2a/fonc-14-1391844-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7d7/11076680/6c8885d4eeb1/fonc-14-1391844-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7d7/11076680/dbcfe748e6e3/fonc-14-1391844-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7d7/11076680/c768807e4b2a/fonc-14-1391844-g003.jpg

相似文献

1
A three miRNAs panel in paraffin tissue serves as tool for predicting prognosis of renal cell carcinoma.石蜡组织中的三种微小RNA组合可作为预测肾细胞癌预后的工具。
Front Oncol. 2024 Apr 24;14:1391844. doi: 10.3389/fonc.2024.1391844. eCollection 2024.
2
MiR-378a-5p acts as a tumor suppressor in renal cell carcinoma and is associated with the good prognosis of patients.MiR-378a-5p在肾细胞癌中作为一种肿瘤抑制因子发挥作用，并与患者的良好预后相关。
Am J Transl Res. 2019 Apr 15;11(4):2207-2218. eCollection 2019.
3
Identification of miR-20a-5p as Robust Normalizer for Urine microRNA Studies in Renal Cell Carcinoma and a Profile of Dysregulated microRNAs.鉴定 miR-20a-5p 作为肾细胞癌尿液 microRNA 研究的稳健归一化因子及失调 microRNAs 谱。
Int J Mol Sci. 2021 Jul 24;22(15):7913. doi: 10.3390/ijms22157913.
4
MiR-31-5p acts as a tumor suppressor in renal cell carcinoma by targeting cyclin-dependent kinase 1 (CDK1).miR-31-5p 通过靶向细胞周期蛋白依赖性激酶 1（CDK1）在肾细胞癌中发挥肿瘤抑制作用。
Biomed Pharmacother. 2019 Mar;111:517-526. doi: 10.1016/j.biopha.2018.12.102. Epub 2018 Dec 28.
5
Associations of high expression of miR-106b-5p detected from FFPE sample with poor prognosis of RCC patients.从 FFPE 样本中检测到的高表达 miR-106b-5p 与 RCC 患者预后不良相关。
Pathol Res Pract. 2019 Jun;215(6):152391. doi: 10.1016/j.prp.2019.03.019. Epub 2019 Mar 19.
6
Combination of tumor suppressor miR-20b-5p, miR-30a-5p, and miR-196a-5p as a serum diagnostic panel for renal cell carcinoma.抑癌 miR-20b-5p、miR-30a-5p 和 miR-196a-5p 的联合作为肾细胞癌的血清诊断标志物。
Pathol Res Pract. 2020 Nov;216(11):153152. doi: 10.1016/j.prp.2020.153152. Epub 2020 Aug 4.
7
Oncogene miR-154-5p regulates cellular function and acts as a molecular marker with poor prognosis in renal cell carcinoma.癌基因 miR-154-5p 调节细胞功能，并作为一种分子标志物，预示肾细胞癌预后不良。
Life Sci. 2018 Sep 15;209:481-489. doi: 10.1016/j.lfs.2018.08.044. Epub 2018 Aug 21.
8
Integrated analysis identifies microRNA-188-5p as a suppressor of AKT/mTOR pathway in renal cancer.综合分析鉴定 microRNA-188-5p 为肾癌细胞中 AKT/mTOR 通路的抑制因子。
Cancer Sci. 2023 Aug;114(8):3128-3143. doi: 10.1111/cas.15832. Epub 2023 May 18.
9
Molecular Characterization of Renal Cell Carcinoma: A Potential Three-MicroRNA Prognostic Signature.肾细胞癌的分子特征：一种潜在的三 miRNA 预后标志物。
Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):464-472. doi: 10.1158/1055-9965.EPI-17-0700. Epub 2018 Feb 12.
10
Identification of a four-microRNA panel in serum for screening renal cell carcinoma.血清中用于筛查肾细胞癌的四个 microRNA 标志物的鉴定。
Pathol Res Pract. 2021 Nov;227:153625. doi: 10.1016/j.prp.2021.153625. Epub 2021 Sep 24.

引用本文的文献

1
The key role of miR‑378 in kidney diseases (Review).miR-378在肾脏疾病中的关键作用（综述）
Mol Med Rep. 2025 Apr;31(4). doi: 10.3892/mmr.2025.13466. Epub 2025 Feb 21.

本文引用的文献

1
Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment.肾细胞癌：流行病学、诊断和治疗概述。
G Ital Nefrol. 2022 Jun 20;39(3):2022-vol3.
2
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.欧洲泌尿外科学会肾癌指南：2022 年更新版。
Eur Urol. 2022 Oct;82(4):399-410. doi: 10.1016/j.eururo.2022.03.006. Epub 2022 Mar 26.
3
miR-378a-5p improved the prognosis and suppressed the progression of hepatocellular carcinoma by targeting the VEGF pathway.微小RNA-378a-5p通过靶向血管内皮生长因子（VEGF）途径改善了肝细胞癌的预后并抑制了其进展。
Transl Cancer Res. 2020 Mar;9(3):1558-1566. doi: 10.21037/tcr.2020.01.46.
4
The tumor suppressor miR-642a-5p targets Wilms Tumor 1 gene and cell-cycle progression in prostate cancer.抑癌基因 miR-642a-5p 靶向 Wilms 瘤基因 1 并抑制前列腺癌细胞周期进程。
Sci Rep. 2021 Sep 9;11(1):18003. doi: 10.1038/s41598-021-97190-x.
5
MiRNAs and Cancer: Key Link in Diagnosis and Therapy.miRNAs 与癌症：诊断与治疗的关键联系
Genes (Basel). 2021 Aug 23;12(8):1289. doi: 10.3390/genes12081289.
6
miRNA interplay: mechanisms and consequences in cancer.miRNA 相互作用：癌症中的机制和后果。
Dis Model Mech. 2021 Apr 1;14(4). doi: 10.1242/dmm.047662. Epub 2021 Apr 15.
7
MicroRNA: A signature for cancer progression.MicroRNA：癌症进展的特征。
Biomed Pharmacother. 2021 Jun;138:111528. doi: 10.1016/j.biopha.2021.111528. Epub 2021 Mar 23.
8
MicroRNA‑642a‑5p inhibits colon cancer cell migration and invasion by targeting collagen type I α1.miRNA-642a-5p 通过靶向Ⅰ型胶原α1 抑制结肠癌细胞迁移和侵袭
Oncol Rep. 2021 Mar;45(3):933-944. doi: 10.3892/or.2020.7905. Epub 2020 Dec 18.
9
miR-378a-5p inhibits the proliferation of colorectal cancer cells by downregulating CDK1.微小RNA-378a-5p通过下调细胞周期蛋白依赖性激酶1抑制结肠癌细胞的增殖。
World J Surg Oncol. 2021 Feb 19;19(1):54. doi: 10.1186/s12957-021-02166-w.
10
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.